IL-27-induced type 1 regulatory T (Tr1) cells suppress autoimmunity by producing IL-10. Signal transducer and activator of transcription (STAT) 1 and STAT3 have been described as key transcription factors that promote IL-10 secretion from Tr1 cells induced by IL-27. However, the molecular pathways for negatively regulating Tr1 cell differentiation remain elusive. Here, we show that IL-27 induces metallothioneins (MTs) that in turn prevent Tr1 cell development. MT expression leads to the reduction of STAT1 and STAT3 phosphorylation under Tr1 differentiation condition, resulting in impaired IL-10 production. Accordingly, Tr1 cells derived from MT-deficient mice showed an increased ability to produce IL-10 and potently suppress experimental autoimmune encephalomyelitis upon adoptive transfer. Moreover, activation of STAT1 and/or STAT3 can overcome the suppression of IL-10 by MTs, indicating a dynamic balance between STATs and MTs in regulating IL-10 during Tr1 cell differentiation.
I L-10-producing type 1 regulatory (Tr1) cells are an emerging regulatory T-cell subset, which was shown by us (1) and others (2) , to be induced by IL-27. They have been proposed to control autoimmunity and tissue inflammation in mouse models of human autoimmune diseases including multiple sclerosis, inflammatory bowel disease and graft-versus-host disease (3) . In addition, Tr1 cells were reported to suppress the induction of cytotoxic effector T cell (CTL) responses and inhibit antitumor immunity (4) . Tr1 cells produce both IFN-γ and IL-10, without expressing the regulatory T-cell (Treg)-specific transcription factor, forkhead box P3 (Foxp3) (5) . Transcriptional analysis of Tr1 cells showed that Tr1 cells differentiated from Tbx21 −/− cells exhibited severely compromised IFN-γ but not IL-10 production, which was in contrast to Stat1 −/− Tr1 cells that showed reduction in both IFN-γ and IL-10 production (6) . More recently, we have discovered that the transcription factors c-Maf and aryl hydrocarbon receptor (AhR), both of which are induced by IL-27, bind to the Il10 promoter, and are essential for the induction of IL-10 in Tr1 cells (1, 7) . In addition, IL-27-induced protooncogene c-Maf (Maf) and Ahr cooperatively bind to the promoter and transactivate the Il21 gene, which acts as a growth factor for the generation of Tr1 cells. Although the molecular landscape for the generation of Tr1 cells is being identified, very little is known about the negative regulation of Tr1 cell development.
To identify candidate molecules that can control Tr1 cell differentiation, we have performed a comparative gene microarray analysis of Tr1 cells generated with IL-27 and identified that isoforms 1 and 2 of metallothionein (MT) were strongly induced in Tr1 cells by IL-27. MT1 and MT2 are low-molecular-weight proteins involved in the detoxification of heavy metals and in the regulation of oxidative stress (8) . There are four different MT genes constitutively expressed in the liver, of which MT1 and MT2 are the most abundantly expressed (9) . MT genes are highly induced under different stresses such as inflammation (9) and are specifically induced by proinflammatory cytokines like TNF-α, IL-1, and IL-6 (10). However, the role of MTs in IL-27-induced Tr1 cell differentiation and IL-10 production is not known.
Here, we show that MTs control IL-10 production as Tr1 cells from MT-deficient mice exhibit increased IL-10 production both in vitro and in vivo. At the mechanistic level, we found that, in the absence of MTs, IL-27 induces increased phosphorylation of STAT1 and STAT3 but not STAT4, resulting in enhanced IL-10 production. Furthermore, compared with WT Tr1 cells, Mt −/− Tr1 cells were more efficient in their ability to suppress effector T cell proliferation and inhibit the development of experimental autoimmune encephalomyelitis (EAE). Taken together, our data suggest that MTs act as negative regulators for IL-27-induced Tr1 cells.
Results
Late Expression of MTs in IL-27-Induced Tr1 Cells. To gain insight into the differentiation of IL-27-induced Tr1 cells, we performed a comparative microarray analysis of developing Tr1 cells at 72 h after stimulation with IL-27. We found that MT1 and -2 were highly expressed in IL-27-induced Tr1 cells generated from naïve CD4
low T cells compared with T cells similarly activated without the presence of differentiating cytokines (Th0) (Fig. S1A) . We then analyzed kinetics of MT1 and MT2 expression during the differentiation of Tr1 cells with IL-27. In contrast to Th0 cells, which express only marginal levels of MT1 and -2, both MT isoforms were highly expressed in IL-27-induced Tr1 cells (Fig. S2) . Although MT expression was dramatically enhanced in Tr1 cells after 72 h, we failed to detect any significant MT expression before 48 h. Interestingly, this delayed induction of MTs coincided with the induction of IL-10 in developing Tr1 cells (Fig. S2) . We also examined the expression levels of MT1 and MT2 in different subsets of CD4 + T cells. We found that both MTs were highly expressed in Tr1 and T helper 17 cells (Th17), whereas Th1 or Th2 cells exhibited modest expression of MT1 and MT2 (Fig. S1B ).
MTs Impair IL-10 Expression in IL-27-Induced Tr1 Cells. We then investigated the role of MTs on IL-27-induced Tr1 cells by differentiating naïve CD4 + T cells from WT or Mt −/− mice. Although IFN-γ production from Tr1 cells was unaffected in the absence of MTs, the frequency of IL-10-producing cells and the secretion of IL-10 were notably enhanced in Tr1 cells derived from Mt −/− mice ( Fig. 1 A and B) . We and others have previously shown that TGF-β1 and IL-6-derived Th17 cells also express IL-10 (11, 12) . MTs are expressed at high levels in Th17 cells differentiated with TGF-β1 and IL-6, whereas MT-deficient Th17 cells did not show a difference in IL-10 or other Th17 cytokines (Fig. S3A) . Addition of recombinant MT1 or MT2 during differentiation of naïve CD4 + T cells with IL-27 severely impaired IL-10 secretion, but it did not affect IFN-γ production. IL-17 secretion from differentiating Th17 cells was not impaired, whereas IL-10 secretion was modestly decreased in cells treated with MT1 or MT2 (Fig. S3B) . Analysis of the signature Tr1 cytokines from WT and Mt −/− Tr1 cell cultures showed increased IL-10 and unchanged IFN-γ production at mRNA level as well. Additionally, we found that both Il21 and Il27r, which are critical for Tr1 cell development (1, 2), were also up-regulated in the absence of MTs (Fig. 1C) . However, other genes that are also expressed in Tr1 cells, like Ahr and Tbx21, are unchanged in the absence of MTs (Fig. 1C) . To assess whether MTs play a role in Tr1 cells generated with other stimuli than IL-27, we differentiated naïve sorted CD4 + T cells using vitamin D3 and dexamethasone (13) . We observed that the Mt −/− Tr1 cells exhibited elevated IL-10 production under both vitamin D3 and dexamethasone stimulation after 72 h. The enhancement of IL-10 became more profound when these two were combined (Fig. S3C) . Altogether, these data indicate that MTs impede IL-10 secretion from Tr1 cells.
We then determined whether endogenous overexpression of MTs can reverse the phenotype we observed in the Mt −/− Tr1 cells. Retroviral overexpression of GFP-tagged MT1 or MT2 in WT T cells under IL-27 stimulation resulted in reduced expression of IL-10 and had no affect on IFN-γ, as detected by intracellular staining and ELISA ( Fig. 1 D and E) . Furthermore, we sorted out the GFP + cells from the MT1 or MT2 retroviral transduced Tr1 cells and examined the expression of other key genes expressed in Tr1 cells. Consistent with MT-deficient T cells, the expression of Il10, Il27r, and Il21 genes was down-regulated, whereas Ahr and IFN-g were unchanged by MT1 or MT2 overexpression (Fig. 1F) . Thus, our data demonstrate that MTs negatively regulate Tr1 differentiation by inhibiting IL-10 production and impairing the IL-27 signaling pathway by repressing Il27r and Il21 expression.
To test whether MTs are also relevant for human Tr1 cell biology, we differentiated human Tr1 cell in vitro to analyze MT expression and the function of MTs in these cells. More than 10 isoforms of MT have been identified in the human genome, compared with only 3 isoforms in the mouse genome. According to the National Center for Biotechnology Information HomoloGene database, human MT1E and MT1H are the closest homologs to murine MT1 and MT2, respectively. Therefore, we decided to test the mRNA expression level of these two isoforms in human Tr1 cells. We observed that Mt1e and Mt1h were highly expressed in human Tr1 cells compared with Th0 cells (Fig. S4A) . To understand the relevance of MTs in human Tr1 cells, we differentiated human Tr1 cells in the presence of recombinant MT1 and MT2 proteins. We observed that both MT1 and MT2 significantly suppressed the IL-10 production of human Tr1 cells (Fig. S4 B and  C) . Moreover, we observed that the supernatants from cultured Tr1 cells inhibited proliferation of bystander CD4 + T cells, whereas the supernatants from the Tr1 cells cultured with additional MT1 or MT2 exhibited reduced ability to suppress proliferation, which was abrogated by anti-IL-10 antibody (Fig. S4D ). These data suggest that the inhibitory functions of human Tr1 cells are also negatively regulated by MTs.
MTs Negatively Regulate STAT1 and STAT3 Activation. Previous studies have shown that STAT1 and STAT3 are both critical for the induction of IL-10 production in Tr1 cells (6, 14) . To assess whether MTs regulate Tr1 differentiation by influencing the activation of STATs, we examined the activation level of STAT1 and STAT3 after IL-27 stimulation. To this end, naïve CD4 + T cells from WT and Mt −/− mice were activated with IL-27 and phosphorylation of STAT1 and STAT3 was analyzed. We found that both STAT1 and STAT3 were hyperphosphorylated upon IL-27 stimulation in Mt −/− compared with WT T cells ( Fig. 2 A and C) . Besides STAT1 and STAT3, STAT4 is also required for IL-10 production (15); however, there was no difference in the levels of pSTAT4 in WT and Mt −/− T cells ( Fig. 2 B and C). These results indicate that MTs may inhibit IL-10 production in Tr1 cells by regulating the activation of STAT1 and STAT3.
To identify a potential relationship between STAT1/3 and MTs during Tr1 cell differentiation, we analyzed T cells from Stat1 MTs Control the Induction of Tr1 Cells in Vivo. To study the relevance of MTs in expanding Tr1 cells in vivo, we examined IL-10-producing Tr1 cells generated from CD4
memory T cells from WT versus Mt −/− mice. We found that IL-10 secretion from memory T cells from Mt −/− mice was increased by over 50% compared with WT mice (Fig. 3A) . It has previously been shown that repeated in vivo treatment with anti-CD3 antibody induces Tr1 cells, which are dependent on IL-27 for their generation (1, 16) . Because MTs are expressed in other tissues, such as liver, it is not clear whether the in vivo increase in IL-10 is due to a direct effect on T cells. To exclude any effects from the nonhematopoietic cell-derived MTs in our system, we generated bone marrow (BM) chimeras in which the WT host were reconstituted with either WT or Mt −/− BM. Eight weeks after reconstitution, we repeatedly administered anti-CD3 or an isotype control antibody to the WT and Mt −/− BM chimera mice. After treatment, we analyzed the Tr1 cell frequency in peyer's patches (PP) and lamina propria (LP). To rule out the confounding effects by other IL-10-producing T-cell subsets and specifically examine Tr1 cells, we analyzed IL-10 production by gating on CD4
+ IL-17 -
Foxp3
-cells. We found a significant increase in Tr1 cells in Mt −/− BM chimera's PP and LP compared with WT chimeras (Fig.  3 B and C) . These results further emphasize that MTs regulate the generation of IL-10 + Tr1 cells by specifically acting on the hematopoietic compartment in vivo.
Enhanced Suppressive Capacity of IL-10 Producing T Cells in the Absence of MT in Vivo. To further understand the role of MTs and their relevance to the function of Tr1 cells in vivo, we studied the impact of MT-deficient Tr1 cells in an adoptive transfer model of EAE. We first immunized WT or Mt −/− mice with myelin oligodendrocyte glycoprotein (MOG) peptide with Freund's Complete Adjuvant (CFA). Ten days following immunization we isolated lymphocytes from immunized WT or Mt −/− mice and reactivated them under various conditions. The response was antigen specific as depicted by the proliferation with MOG but not with OVA peptide (Fig. 4 A-D) . When these cells were restimulated by MOG 35-55 and IL-23, which has been reported to induce and reactivate Th17 cells (17) , IL-17 production from CD4 + T cells was not altered (Fig. 4 A  and B) . Although we did not see a significant change in IL-10 production with specific antigen MOG 35-55 by flow cytometry, we indeed observed a higher production of IL-10 in CD4 + T cells from Mt −/− mice than WT mice when T cells were reactivated in the presence of MOG 35-55 in the cultured supernatant, which was further amplified in the presence IL-27 ( Fig. 4 C and D) . Moreover, IFN-γ production by cells from WT and Mt −/− mice was comparable following either stimulation condition (Fig. 4 A-D) . Consistent with our in vitro data, these results confirm the specific role MTs play in the regulation of IL-10 in IL-27-stimulated Tr1 cells.
Next, we tested whether Mt −/− Tr1 cells display enhanced ability to suppress autoimmunity because IL-10 production has been used as a criterion for Tr1 cell anti-inflammatory activity. We first generated pathogenic effector T cells from MOG-immunized WT mice. Simultaneously, WT or Mt −/− T cells were cultured in the presence of MOG and IL-27 to generate antigen specific Tr1 cells. Because Mt −/− mice are on the SV129 background and this strain is not optimal for EAE induction by MOG 35-55 (18), we used an alternative recipient strain (SV129 × B6) F1, which were genetically compatible with SV129 and were susceptible to EAE following adoptive transfer (19) . We then adoptively transferred WT effector T cells with or without differentiated Tr1 cells from either WT or Mt −/− mice at a ratio of 3:1. As expected, WT Tr1 cells significantly suppressed EAE development. However, Mt −/− Tr1 cells suppressed disease more efficiently than WT Tr1 cells both in terms of disease severity and incidence (Fig. 4E) . We further tested the ability of Tr1 cells to suppress EAE by titrating the Tr1 cells. Mt −/− Tr1 cells exhibited the suppressive capacity on the disease process, whereas the suppressive effect of WT Tr1 cells was no longer dominant when the ratio of the effector T cells (Teff)-to-Tr1 was 5:1 (Fig. S5) . Using the same adoptive transfer system, we labeled WT effector cells with carboxyfluorescein diacetate succinimidyl ester (CFSE) before transfer. On day 4 after transfer, lymphocytes were isolated from lymph nodes of the recipient mice and CFSE + effector cell proliferation was analyzed. We found significant reduction of effector cell proliferation if they had been transferred together with Tr1 cells. Moreover, Mt −/− Tr1 cells displayed a superior suppressive capacity, inhibiting effector T cell proliferation more profoundly compared with WT Tr1 cells (Fig. 4F) .
Discussion
As one of the suppressive T cell subsets, Tr1 cells have been described to regulate inflammation, graft-versus-host disease, and autoimmunity by producing IL-10 (3). The results presented in this study show that the nonenzymatic proteins MT1 and MT2 can negatively regulate the production of IL-10 but not IFN-γ during Tr1 cells' development and thus regulate the anti-inflammatory properties of those cells. Loss of MT1 and MT2 enhanced IL-10 production within Tr1 cells upon IL-27 or vitamin D3/dexamethasone stimulation without affecting IFN-γ. Furthermore, the enhancement of IL-10 increases the capacity of MT-deficient Tr1 cells to suppress effector T cells, in turn leading to the abatement of autoimmunity. Our results reveal that MTs blunt IL-10 secretion from Tr1 cells by preventing the activation of the transcription factor STAT1 and STAT3. Consistent with these data, anti-CD3-induced generation of Tr1 cells was increased in the absence of MTs in vivo, underscoring the key role of MTs in regulating IL-10 production in Tr1 cells.
Although the key roles of MTs in mediating heavy metal detoxification have been abundantly documented (20) , their implication in the control of gene transcription is still unclear. It has been proposed that MT could bind to the p50 subunit of the NF-κB complex, thereby increasing its ability to act as a transcriptional activator (21) . So far, there is no evidence showing that MTs have any DNA-binding sites, making it unlikely that they directly regulate gene expression. However, it has been shown that MTs can control the binding of the estrogen receptor to its DNA-binding site by modulating zinc levels (22) . Our data suggest that MTs regulate induction of pSTAT1 and pSTAT3, both of which are required for induction of many important cytokinedriven functions in T cells. Whether MTs directly bind to STAT1 or STAT3 and interfere with their phosphorylation or indirectly by interfering with Jak-mediated phosphorylation is not clear at this stage. However, because it was reported that Zinc binding disrupts the association of STAT3 with Jak2 kinase (23), we can speculate that zinc might be involved in the MT-driven inhibition of phosphorylation of STAT1/3. Nonetheless loss of MTs resulted in enhanced phosphorylation and transcription of STAT1 and STAT3, suggesting STAT1/3 but not STAT4 as one of the targets of MTs. Although MTs are also expressed in Th17 cells, MT expression does not regulate the expression of proinflammatory proteins such as IL-17. We cannot rule out the effect of MTs in IL-10 production by Th17 cells, because IL-6 is one of the cytokines that induces IL-10 and activation of STAT3 in Th17 cells (24) .
Proinflammatory cytokines such as IL-6 induce MTs by activating the transcription factor STAT1 and STAT3 (10) . Endotoxin (LPS) produced during bacterial infection has also been shown to elevate the MT expression level (10) . Both LPS and IL-6 can initiate STAT1 and STAT3 expression and activation. pSTAT1 and pSTAT3 in turn can directly bind to the promoter of MTs and potentiate its transcription (10), forming a feedback inhibitory loop whereby STAT1/3 induction of MTs results in decreased induction and/or activation of STAT1/3. This mechanism of action would be reminiscent of the action of the suppressors of cytokine signaling 3 (SOCS3), which is induced by STAT3 and limits STAT3 phosphorylation, thereby dampening the secretion of proinflammatory cytokines like IL-17 (25) . Here, the induction of MTs by IL-27 would limit the induction of Tr1 cells to prevent excessive immune regulation that might favor the emergence of viral infections or cancers.
Both STAT1 and STAT3 are phosphorylated upon IL-27 signaling differentiation. MTs possibly function at the later stage of Tr1 cell development by their temporal expression profile in Tr1 cells. It has been described that MT proteins play significant roles during different inflammatory conditions, such as collageninduced arthritis (CIA) (26) or EAE (27) , but the function of MTs within different cell compartments varies. During CNS inflammation, it has been reported that MTs play an important role for EAE recovery, because MT proteins were found to be elevated within the CNS, specifically in astrocytes and activated macrophages (27) . Together with the Zn-MT2 treatment resulting in EAE reduction, this result implicates that MTs have a strong neuroprotective effect within the CNS (28) . Moreover, in the absence of MTs, mice exhibited enhanced production of proinflammatory cytokines such as IL-1 and TNF-α, which in turn can lead to inhibition of leukocyte recruitment and ameliorate EAE (29, 30) . In this study, we established the correlation between MTs and IL-10 production within Tr1 cells and their proinflammatory role in the EAE model. Passive transfer EAE experiments allowed us to dissect the function of MTs specifically in T cells, excluding any effects due to the neuroprotective role of MTs. We and others have shown that the repetitive administration of anti-CD3 antibody can induce Tr1 cells in the gut (1, 16) . Repetitive administration of anti-CD3 induced Tr1 cells in the gut more efficiently when we used Mt −/− BM chimera compared with Mt −/− mice, further emphasizing the importance of the cellular environment in the control of MT responses. These data further suggest that MTs have divergent functions in the immune response, depending on tissue and cells. It is also important to evaluate distinct effects of MTs in specific circumstances to identify all of their various and sometimes contradicting functions. Altogether, we have identified MT1 and MT2 as negative regulators of Tr1 cell differentiation and IL-10 production. We also illustrate the balance between MT and STAT signaling in controlling Tr1 cell development. Our work emphasizes that MTs, beyond their essential role in the regulation of metal homeostasis, also shape the quality of immune responses in vivo. By identifying a specific function for MTs in Tr1 cells, our study also provides a target for development of selective therapeutic strategies for regulating Tr1 cell expansion and autoimmunity. (30 pg/mL; Sigma) for Tr1 cells; human TGF-β1 (2 ng/mL) and mouse IL-6 (20 ng/mL) for Th17 differentiation; mouse IL-12 (5 ng/mL) and anti-mouse IL-4 (10 μg/mL; 11B11) for Th1 differentiation; or mouse IL-4 (10 ng/mL) and antimouse IL-12 (10 μg/mL; C17.8) for Th2 differentiation; or human TGF-β1 (2 ng/mL) for iTregs. All recombinant cytokines were purchased from R&D Systems.
Statistical Analysis. Statistical analysis was performed using Prism software (GraphPad). P values < 0.05 were considered significant. Measurement of Cytokines. Secreted cytokines were measured by ELISA at the indicated times. For intracellular cytokine staining, cells were cultured as described above and stimulated for 4 h at 37°C in culture medium containing Phorbol 12-myristate 13-acetate (50 ng/mL; Sigma), ionomycin (1 μg/mL; Sigma), and monensin (GolgiStop; 1 μL/mL; BD Biosciences). After staining for surface markers, cells were fixed and permeabilized according to the manufacturer's instructions (BD Biosciences). All cytokine antibodies were purchased from Biolegend.
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Phospho-STAT Staining for FACS. FACS-sorted naïve CD4
+ T cells from WT or Mt −/− mice spleen were either left unstimulated or stimulated with IL-27 for 20 min. Levels of phosphorylated proteins were detected by staining with anti-pSTAT3 (pY705), anti-pSTAT1 (pY701), and anti-pSTAT4 (pY693) (all from BD Biosciences) following the manufacturer's instructions.
Quantitative RT-PCR. RNA was extracted with RNAeasy minikits (Qiagen) and RNA expression levels were analyzed by RT-PCR according to the manufacturer's instructions using the GeneAmp 7500 Sequence Detection System or the ViiA7 Real-Time PCR System (Applied Biosystems). Expression was normalized to the expression of β-actin. Primers-probe mixtures were purchased from Applied Biosystems: Ahr (Mm00478930-mL); Ifng (Mm99999071-m1); Il10 (Mm00439615-g1); Il21 (Mm00517640-m1); Il27ra (Mm00497259-m1); Mt1 (Mm00496660-g1); Mt2 (Mm00809556-s1); Maf (Mm02581355-S1); Tbx21 (Mm00450960-m1); Actb (Mm00446968-m1); Mt1e (Hs01938284_g1); Mt1h (Hs00823168_g1). Retroviral Transduction. Retroviral particles were produced by transiently transfecting HEK 293T cells with retroviral packaging constructs and expression plasmids MSCV-IRES-GFP or MSCV-IRES-GFP-MT1/MT2 using Fugene HD (Roche). Seventy-two hours after transfection, viral culture supernatants were harvested, supplemented with polybrene (8 mg/mL), and added to previously stimulated T cells (5 ×10 5 per well, plate-bound anti-CD3/CD28 and IL-27 for 24 h). Cultures were centrifuged at 800 × g for 45 min at 25°C. anti-CD3/CD28 (1 μg/mL). Neutralizing anti-IL-10 antibody (20 μg/mL) was added to the indicated condition, and proliferation was measured at day 5 by thymidine incorporation. Data represent one of two experiments involving seven randomly selected donors. *P < 0.05 (Student t test. Error bars, mean ± SD). 
